In Depth 13 Aug 2025 Injecting hope into skin cancer treatment: The promise of melanoma vaccines Discover how melanoma vaccines are gaining traction in the clinic and could soon become a treatment option for this deadly skin cancer. August 13, 2025 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 7 May 2025 Unlocking immunity: the power of TLR agonists Let us delve into some of the TLR agonists in the clinic and why the careful selection of these drugs is crucial. May 7, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 19 Mar 2025 Breast cancer treatments heat up: Five therapies poised to transform patient outcomes Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different approaches. March 19, 2025 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 12 Mar 2025 Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field. March 12, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 17 Jan 2025 Are PD-1 and PD-L1 checkpoint inhibitors as good as we thought? Checkpoint inhibitors, especially those targeting PD-1 and PD-L1, are exploding in popularity. But how much of it is hype? January 17, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 11 Dec 2024 Targeting sugar molecules: Can glycobiology lead to a new era for cancer immunotherapy? Find out more about the emerging field of glycobiology, which could potentially lead to a new type of cancer immunotherapy. December 11, 2024 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 4 Sep 2024 2024: a year of breakthroughs for endometrial cancer? New treatments have been approved by regulators for endometrial cancer, which are regarded as major therapeutic breakthroughs. September 4, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 27 Aug 2024 Could microbiome drugs be the key to unlocking checkpoint inhibitors’ potential? As Microbiotica announces phase 1 approval for two microbiome drugs we delve into their potential in oncology and beyond. August 27, 2024 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2023 IOME Bio claims breakthrough in cancer research IOME Bio, a French seed stage biotechnology company focused on overcoming tumor resistance to immune checkpoint inhibition, has published its foundational research by founders Arlene Sharpe and Dennis Kasper in Nature. The company said its work reveals unique insights into the critical importance of the RGMb/PD-L2 pathway in immunotherapy resistance and further strengthens the significance […] June 15, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Mar 2023 Orphan drug designation for Laevoroc metabolic immune checkpoint inhibitor Laevoroc Immunology, a privately-owned, Swiss oncology development company, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for immune checkpoint inhibitor LR 09. LR 09 is a novel metabolic immune checkpoint inhibitor, for the treatment of patients with hematological malignancies who are diagnosed with a relapse after allogeneic stem […] March 3, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2023 Next-generation small molecules hold promise for immunotherapy By Ian B. Walters, chief executive officer and chairman, Portage Biotech In recent years, PD-1/PD-L1 checkpoint antibody therapies have revolutionized the immuno-oncology landscape and offered cancer patients the hope for a long term treatment and cure of their disease. While these treatments have shown great promise in reversing T-cell exhaustion, many patients still have limited […] February 1, 2023 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jan 2023 DeuterOncology closes financing round to start lung cancer study DeuterOncology, a clinical-stage drug development company, has closed €5.65 million ($6.1 million) series A financing, to start the phase I clinical study for its lead product DO-2, an improved MET kinase inhibitor currently being developed as a potential best-in-class targeted therapy for lung cancer. The financing included participation from historical investor Newton Biocapital and new […] January 20, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email